Bone Biologics Corp., a developer of orthobiologic products for spine fusion markets, has engaged Avania as the contract research organization (CRO) for the Company’s clinical trial with NB1. Avania is an integrated global, full-service CRO with specialized expertise in medical devices, novel technology and drug-device combination products. The trial will evaluate the safety and effectiveness of Bone Biologic’s novel NB1 in patients with degenerative disc disease undergoing a Transforaminal Lumb...